Lytix Biopharma presents fourth quarter and second half 2022 results
Oslo, 16 February 2023. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company, today releases its fourth quarter and second half 2022 results – Steady progress towards improving cancer treatment outcomes.“Our molecules have a unique dual mode of action and can kill cancer cells in a way that activates a broad T-cell response that has the potential to target all cancer cells within heterogeneous tumors and thereby increase the number of patients responding to immunotherapy. We have seen very promising effects in cancer patients and are now eagerly